University of Florence

Aspargo Laboratories Inc. Announces Initial Dosing of All Subjects in Bioavailability Study for Sildenafil Oral Suspension

Retrieved on: 
Tuesday, September 19, 2023
Sildenafil, Volunteering, University, Prevalence, Tablet, University of Florence, Absorption, Stomach, Male, Erectile dysfunction, FDA, ED, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

A companion food-effect study will assess the rate and extent of absorption of ASP-001 under fasted versus fed conditions.

Key Points: 
  • A companion food-effect study will assess the rate and extent of absorption of ASP-001 under fasted versus fed conditions.
  • “Completion of initial dosing of all 47 subjects in this important study represents a significant milestone in our late-stage development program of Sildenafil Oral Suspension for the treatment of ED,” said Michael Demurjian, Chief Executive Officer and Chairman of Aspargo.
  • We look forward to completing this comparative bioavailability study and initiating our companion food-effect study shortly and sharing results from both studies later this year.”
    Sildenafil Oral Suspension is an oral liquid suspension of sildenafil citrate administered via a metered-dose pump that dispenses 12.5 mg of sildenafil per actuation.
  • Aspargo uses a metered-dose container that delivers the precise amount of sildenafil citrate per actuation based on patient need.

MicroPort Orthopedics Releases Renowned Speaker Lineup for Second Annual Global Medial-Pivot Symposium

Retrieved on: 
Wednesday, September 20, 2023
Surgeon, University, Stanford University, University of Leeds, University of Florence, Evolution, Research, Massachusetts General Hospital, MD, Patient, Pain management, Faculty, Hospital, Robotics, Health, Medical device, Nursing

ARLINGTON, Tenn., Sept. 20, 2023 /PRNewswire/ -- MicroPort Orthopedics, a global leader in Medial-Pivot Knee Technology, today announces the full agenda and line-up of world-renowned surgeons speaking at its second annual Global Medial-Pivot Symposium, October 13-14, 2023, in Phoenix, Arizona. This event will highlight the Evolution® Medial-Pivot knee design principles and scientific evidence, personalized surgical approaches including alignment strategies, advanced digital technologies, and improved patient care pathways. The two-day educational event will include faculty-led discussions, an evening event celebrating the 25th anniversary of the Medial-Pivot technology, and engaging breakout sessions.

Key Points: 
  • ARLINGTON, Tenn., Sept. 20, 2023 /PRNewswire/ -- MicroPort Orthopedics , a global leader in Medial-Pivot Knee Technology, today announces the full agenda and line-up of world-renowned surgeons speaking at its second annual Global Medial-Pivot Symposium , October 13-14, 2023, in Phoenix, Arizona.
  • This event will highlight the Evolution ® Medial-Pivot knee design principles and scientific evidence, personalized surgical approaches including alignment strategies, advanced digital technologies, and improved patient care pathways.
  • We're excited to come together to explore the most innovative developments in our industry," said symposium steering committee chair Lowry Barnes, MD.
  • MicroPort Orthopedics offers various products and techniques to help patients receiving total hip and knee replacements achieve Full Function, Faster®.

Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

Retrieved on: 
Monday, June 26, 2023
Biotechnology, Pharmaceutical, Health, Exercise, Bristol Myers Squibb, NYHA, University, Heart failure, Civil service commission, Meyer Children's Hospital, Stroke, University of Florence, Quality of life, Boxed, Arrhythmia, Science, BMY, New York Heart Association Functional Classification, Capsule, Dizziness, Patient, Cardiology, Hospital, EC, HCM, NYSE, European Commission, Safety, Fatigue, Pharmaceutical industry, EU

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.
  • The EC approval of CAMZYOS is based upon positive efficacy and safety results from two Phase 3 trials, EXPLORER-HCM and VALOR-HCM.
  • “Obstructive HCM is a life-changing disease for many patients who suffer from symptoms that can significantly impact their quality of life.
  • Bristol Myers Squibb thanks the patients and investigators involved in both clinical trials.

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Retrieved on: 
Monday, June 12, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, FACIT, RBC, TET2, University, MOA, Telomerase, ESA, Reverse transcriptase, TI, Erythropoiesis-stimulating agent, Chromosome, Bone marrow, Neuropsychological test, Mutation, TA, Publication, MF, VAF, MDS, ASXL1, Patient, Risk, Anemia, EHA, Therapy, Biology, University of Florence, Cochran–Mantel–Haenszel statistics, Gene, Thrombocytopenia, News, IPSS, Fatigue, Disease, Silviculture, Medical device, Pharmaceutical industry, Nursing, DNMT3A, SF3B1, Imetelstat

This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.

Key Points: 
  • This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.
  • For patients treated with imetelstat, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue.
  • Further, patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks).
  • In addition to these IMerge Phase 3 presentations, Geron collaborators presented a translational analysis from a subset of IMerge Phase 2 patients, as well as imetelstat myelofibrosis (MF) pre-clinical results.

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D'Andrea to its Board of Directors

Retrieved on: 
Tuesday, May 23, 2023
Inflammation, GSK, Antigen, University, Therapy, ARCH Venture Partners, Biotechnology, Cancer, University of Florence, TCR, SRI International, Discovery, Bangladesh Technical Education Board, Publication, Novartis, Patient, Wistar Institute, Drug discovery, Growth, Immunology, University of Siena, Pharmaceutical industry

BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.

Key Points: 
  • BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.
  • Dr. D'Andrea has over 25 years of experience in the life-science industry including immunology research, drug discovery and development, and strategic leadership in biotechnology and pharmaceutical companies.
  • She is a Venture Partner at Longwood Fund and is the former President and Chief Scientific Officer of ImmuneID.
  • Dr Annalisa D'Andrea, Member of the Board of Directors at Engimmune Therapeutics commented: "I am delighted to be joining Engimmune Therapeutics at an exciting and important phase of development as the Company strives to develop new multi-specific TCR therapies for the treatment and benefit of patients with cancer and autoimmune diseases.

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D'Andrea to its Board of Directors

Retrieved on: 
Tuesday, May 23, 2023
Inflammation, GSK, Antigen, University, Therapy, ARCH Venture Partners, Biotechnology, Cancer, University of Florence, TCR, SRI International, Discovery, Bangladesh Technical Education Board, Publication, Novartis, Patient, Wistar Institute, Drug discovery, Growth, Immunology, University of Siena, Pharmaceutical industry

BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.

Key Points: 
  • BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.
  • Dr. D'Andrea has over 25 years of experience in the life-science industry including immunology research, drug discovery and development, and strategic leadership in biotechnology and pharmaceutical companies.
  • She is a Venture Partner at Longwood Fund and is the former President and Chief Scientific Officer of ImmuneID.
  • Dr Annalisa D'Andrea, Member of the Board of Directors at Engimmune Therapeutics commented: "I am delighted to be joining Engimmune Therapeutics at an exciting and important phase of development as the Company strives to develop new multi-specific TCR therapies for the treatment and benefit of patients with cancer and autoimmune diseases.

Genius Group Announces Strategic Partnership with Swiss School of Business and Management to launch International DBA

Retrieved on: 
Wednesday, March 15, 2023
University of St. Gallen, Learning, Accreditation Council, International, Artificial intelligence, Business analytics, NYSE, Business, Partnership, SSBM, Business school, DBA, Curriculum, Accreditation, The New York Times, Business administration, MBA, University, University of Florence, Accreditation Council for Business Schools and Programs, Student, Faculty, Pennsylvania State University, UAV, Entrepreneurship, Specialization, American University of Rome, ACBSP, Data science, Machine learning, International Doctorate in Translation Studies, Management

SINGAPORE, March 15, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, and its subsidiary GeniusU, announces the launch of its International Doctor of Business Administration (DBA) program in strategic partnership with Swiss School of Business and Management (SSBM).

Key Points: 
  • SINGAPORE, March 15, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, and its subsidiary GeniusU, announces the launch of its International Doctor of Business Administration (DBA) program in strategic partnership with Swiss School of Business and Management (SSBM).
  • This association is aligned with Genius Group’s lifelong learning vision on empowering professional and personal success for all students seeking to build their entrepreneurial careers.
  • The DBA program has a blend of online learning combined with thesis support from dedicated thesis supervisors from SSBM, Geneva.
  • Roger Hamilton, CEO of Genius Group said, “We are excited to partner with Swiss School of Business and Management Geneva to bring this International DBA program to our learners and expand our network of top universities.

Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands

Retrieved on: 
Tuesday, January 24, 2023
Prevalence, Medical device, Erectile dysfunction, Syneos Health, Pharmacist, ED, University of Florence, Physician, Patient, Focus, University, Pharmaceutical industry, Birth control, EU

ENGLEWOOD CLIFFS, N.J., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Aspargo Laboratories, Inc. (“Aspargo”), a privately held specialty pharmaceutical company focused on commercializing innovative formulations of leading tablet medications, announced today that the German Federal Institute for Drugs and Medical Devices has authorized the marketability of “Hezkue™ 12.5 mg per actuation, oral suspension” in Germany effective as of January 12, 2023. The German market – the largest in the EU – represents an important element of Aspargo’s global expansion strategy. Recently, Aspargo received corresponding approvals in Ireland and the Netherlands.

Key Points: 
  • The German market – the largest in the EU – represents an important element of Aspargo’s global expansion strategy.
  • Brand names used to market a drug are subject to approval of the respective health authorities in each country.
  • Sildenafil Spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil per push.
  • Aspargo uses a metered-dose container that delivers the precise amount of sildenafil citrate per push based on patient need.

Partnership of BC Platforms, Euformatics, and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

Retrieved on: 
Thursday, December 1, 2022
IP, University of Milano-Bicocca, Union, Quality control, University, DNA sequencing, Hospital, R, Partnership, Patient, Medical school, USD, Neoplasm, Oncology, Pharmacy, Genomics, University of Florence, Medicine, MIT, Erasmus MC, Medical University of Graz, Pathology, Cancer Research Institute, Cancer, BCP, Precision medicine, NGS, Research, Framework Programmes for Research and Technological Development, EUR, Pharmaceutical industry

This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.

Key Points: 
  • This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.
  • Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms vision for improving cancer patients' diagnostics.
  • BC Platforms, Euformatics, and Oncompass Medicine, have been working on designing the solution.
  • The consortium of BC Platforms, Euformatics and Oncompass Medicine was selected from several highly competitive applications, which were assessed in a multi-step peer-reviewed process.

Partnership of BC Platforms, Euformatics, and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

Retrieved on: 
Thursday, December 1, 2022
IP, University of Milano-Bicocca, Union, Quality control, University, DNA sequencing, Hospital, R, Partnership, Patient, Medical school, USD, Neoplasm, Oncology, Pharmacy, Genomics, University of Florence, Medicine, MIT, Erasmus MC, Medical University of Graz, Pathology, Cancer Research Institute, Cancer, BCP, Precision medicine, NGS, Research, Framework Programmes for Research and Technological Development, EUR, Pharmaceutical industry

This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.

Key Points: 
  • This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.
  • Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms vision for improving cancer patients' diagnostics.
  • BC Platforms, Euformatics, and Oncompass Medicine, have been working on designing the solution.
  • The consortium of BC Platforms, Euformatics and Oncompass Medicine was selected from several highly competitive applications, which were assessed in a multi-step peer-reviewed process.